BP | BP | oil and gas | oil spill | 2015 | DOJ | $20,800,000,000 |
BP | BP | oil and gas | oil spill | 2012 | private lawsuit-federal | $7,800,000,000 |
Royal Bank of Scotland PLC | NatWest Group PLC | financial services | toxic securities abuses | 2017 | FHFA | $5,500,000,000 |
Royal Bank of Scotland Group plc | NatWest Group PLC | financial services | toxic securities abuses | 2018 | DOJ_CIVIL | $4,900,000,000 |
BP | BP | oil and gas | oil spill | 2015 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $4,900,000,000 |
BP Exploration and Production Inc. | BP | oil and gas | oil spill | 2012 | DOJ | $4,000,000,000 |
GlaxoSmithKline Holdings (Americas) | GSK plc | pharmaceuticals | tax violations | 2006 | IRS | $3,400,000,000 |
BP EXPLORATION/MOEX/TRANSOCEAN DEEPWATER/TRITON/GULF OF MEXICO OIL SPILL/DEEPWATER HORIZON (NC) | BP | oil and gas | environmental violation | 2016 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,377,250,000 |
BP Exploration & Production Inc. (Gulf of Mexico Oil Spill) (National Case) (Lead) | BP | oil and gas | environmental violation | 2016 | EPA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $3,372,250,000 |
GlaxoSmithKline LLC | GSK plc | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | FDA | $3,000,000,000 |
GSK PLC | GSK plc | pharmaceuticals | drug or medical equipment safety violation | 2024 | private lawsuit-state | $2,200,000,000 |
Barclays Capital, Inc. | Barclays | financial services | toxic securities abuses | 2018 | USAO | $2,000,000,000 |
BP | BP | oil and gas | oil spill | 2015 | MS-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $1,500,000,000 |
Reckitt Benckiser Group plc | Reckitt Benckiser | household and personal care products | Controlled Substances Act violation | 2019 | USAO | $1,347,000,000 |
HSBC Holdings plc HSBC Bank USA N.A. | HSBC | financial services | anti-money-laundering deficiencies | 2012 | DOJ_CRIMINAL | $1,256,000,000 |
GlaxoSmithKline | GSK plc | pharmaceuticals | drug or medical equipment safety violation | 2010 | private lawsuit-federal | $770,000,000 |
HSBC | HSBC | financial services | toxic securities abuses | 2018 | USAO | $765,000,000 |
SB Pharmco Puerto Rico Inc. | GSK plc | pharmaceuticals | drug or medical equipment safety violation | 2010 | FDA | $750,000,000 |
Barclays PLC | Barclays | financial services | price-fixing or anti-competitive practices | 2015 | DOJ_CRIMINAL | $710,000,000 |
BP | BP | oil and gas | air pollution violation | 2001 | EPA | $660,000,000 |
Standard Chartered Bank | Standard Chartered | financial services | economic sanction violation | 2019 | OFAC | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $657,040,033 |
British American Tobacco | British American Tobacco | tobacco | economic sanction violation | 2023 | DOJ_NATSEC | $629,000,000 |
Indivior Solutions | Indivior PLC | pharmaceuticals | False Claims Act and related | 2020 | DOJ_CIVIL | $589,000,000 |
Republic New York Securities | HSBC | financial services | fraud | 2001 | USAO | $569,000,000 |
HSBC North America Holdings Inc. | HSBC | financial services | toxic securities abuses | 2014 | FHFA | $550,000,000 |
BP | BP | oil and gas | investor protection violation | 2012 | SEC | $525,000,000 |
AstraZeneca LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | FDA | $520,000,000 |
HSBC Bank USA, N.A. | HSBC | financial services | banking violation | 2012 | OCC | $500,000,000 |
Royal Bank of Scotland | NatWest Group PLC | financial services | toxic securities abuses | 2018 | NY-AG | $500,000,000 |
Barclays Bank PLC | Barclays | financial services | price-fixing or anti-competitive practices | 2015 | NY-DFS | $485,000,000 |
Household Finance Corp. | HSBC | financial services | mortgage abuses | 2002 | MULTI-AG | $484,000,000 |
GlaxoSmithKline | GSK plc | pharmaceuticals | off-label or unapproved promotion of medical products | 2012 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $477,792,391 |
HSBC Bank USA NA | HSBC | financial services | mortgage abuses | 2016 | DOJ | $470,000,000 |
BP West Coast Products LLC | BP | oil and gas | consumer protection violation | 2019 | private lawsuit-state | $409,000,000 |
BP North America Inc. | BP | oil and gas | air pollution violation | 2012 | EPA | $408,000,000 |
BAE Systems plc | BAE Systems | aerospace and military contracting | Foreign Corrupt Practices Act | 2010 | DOJ_CRIMINAL | $400,000,000 |
Barclays | Barclays | financial services | price-fixing or anti-competitive practices | 2015 | CFTC | $400,000,000 |
Reckitt Benckiser Group | Reckitt Benckiser | household and personal care products | False Claims Act and related | 2019 | MULTI-AG | $400,000,000 |
Royal Bank of Scotland plc | NatWest Group PLC | financial services | price-fixing or anti-competitive practices | 2015 | DOJ_CRIMINAL | $395,000,000 |
Indivior Inc. | Indivior PLC | pharmaceuticals | price-fixing or anti-competitive practices | 2024 | private lawsuit-federal | $385,000,000 |
Barclays Bank PLC | Barclays | financial services | price-fixing or anti-competitive practices | 2018 | private lawsuit-federal | $384,000,000 |
HSBC Holdings | HSBC | financial services | economic sanction violation | 2012 | OFAC | $375,000,000 |
Barclays Bank PLC | Barclays | financial services | investor protection violation | 2022 | SEC | $361,000,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | False Claims Act and related | 2003 | DOJ_CIVIL | $354,900,000 |
BARCLAYS BANK PLC | Barclays | financial services | price-fixing or anti-competitive practices | 2015 | FED | $342,000,000 |
Standard Chartered Bank | Standard Chartered | financial services | anti-money-laundering deficiencies | 2012 | NY-DFS | $340,000,000 |
Barclays Capital Inc. | Barclays | financial services | toxic securities abuses | 2015 | NCUA | $325,000,000 |
Royal Bank of Scotland plc | NatWest Group PLC | financial services | price-fixing or anti-competitive practices | 2013 | CFTC | $325,000,000 |
BP Products North America Inc. | BP | oil and gas | price-fixing or anti-competitive practices | 2007 | CFTC | $303,000,000 |
British Airways PLC | International Airlines Group | airlines | price-fixing or anti-competitive practices | 2007 | DOJ_ANTITRUST | $300,000,000 |
Standard Chartered Bank | Standard Chartered | financial services | anti-money-laundering deficiencies | 2014 | NY-DFS | $300,000,000 |
Indivior plc | Indivior PLC | pharmaceuticals | off-label or unapproved promotion of medical products | 2021 | MULTI-AG | $300,000,000 |
Barclays Bank PLC | Barclays | financial services | economic sanction violation | 2010 | DOJ_CRIMINAL | $298,000,000 |
De Beers Group | Anglo American PLC | mining and minerals | price-fixing or anti-competitive practices | 2008 | private lawsuit-federal | $295,000,000 |
Standard Chartered Bank | Standard Chartered | financial services | economic sanction violation | 2019 | DOJ_CRIMINAL | $292,210,160 |
Standard Chartered Bank | Standard Chartered | financial services | economic sanction violation | 2019 | NY-MANDA | $292,000,000 |
Royal Bank of Scotland plc | NatWest Group PLC | financial services | price-fixing or anti-competitive practices | 2014 | CFTC | $290,000,000 |
HSBC Holdings PLC | HSBC | financial services | price-fixing or anti-competitive practices | 2018 | private lawsuit-federal | $285,000,000 |
Barclays Bank PLC | Barclays | financial services | toxic securities abuses | 2014 | FHFA | $280,000,000 |
Roxane Laboratories Inc. | Hikma Pharmaceuticals | pharmaceuticals | False Claims Act and related | 2010 | DOJ_CIVIL | $280,000,000 |
HSBC Bank | HSBC | financial services | price-fixing or anti-competitive practices | 2014 | CFTC | $275,000,000 |
Royal Bank of Scotland Group | NatWest Group PLC | financial services | consumer protection violation | 2014 | private lawsuit-federal | $275,000,000 |
ROYAL BANK OF SCOTLAND PLC | NatWest Group PLC | financial services | banking violation | 2015 | FED | $274,000,000 |
PricewaterhouseCoopers | PricewaterhouseCoopers | business services | benefit plan administrator violation | 2023 | private lawsuit-federal | $267,000,000 |
BP | BP | oil and gas | consumer protection violation | 2012 | AK-AG | $255,000,000 |
Royal Bank of Scotland Group | NatWest Group PLC | financial services | price-fixing or anti-competitive practices | 2018 | private lawsuit-federal | $255,000,000 |
HSBC Bank USA, National Association | HSBC | financial services | banking violation | 2013 | OCC | $249,000,000 |
BP Products North America Inc. | BP | oil and gas | air pollution violation | 2023 | EPA | $242,000,000 |
Standard Chartered Bank | Standard Chartered | financial services | economic sanction violation | 2012 | DOJ_CRIMINAL | $227,000,000 |
Janus Capital Management | Janus Henderson | financial services | investor protection violation | 2004 | MULTI-AG | $225,000,000 |
AstraZeneca Pharmaceuticals LP | AstraZeneca | pharmaceuticals | off-label or unapproved promotion of medical products | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $218,092,993 |
Barclays PLC | Barclays | financial services | price-fixing or anti-competitive practices | 2012 | CFTC | $200,000,000 |
Reckitt Benckiser Group | Reckitt Benckiser | household and personal care products | Controlled Substances Act violation | 2019 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $200,000,000 |
AstraZeneca | AstraZeneca | pharmaceuticals | drug or medical equipment safety violation | 2010 | private lawsuit-federal | $198,000,000 |
HSBC Private Bank (Suisse) SA | HSBC | financial services | tax violations | 2019 | USAO | $192,350,000 |
HSBC Holdings plc | HSBC | financial services | economic sanction violation | 2012 | NY-MANDA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $187,500,000 |
Standard Chartered Bank | Standard Chartered | financial services | economic sanction violation | 2019 | NY-DFS | $180,000,000 |
Lloyds TSB Bank PLC | Lloyds Banking Group | financial services | economic sanction violation | 2009 | DOJ_CRIMINAL | $175,000,000 |
HSBC Holdings | HSBC | financial services | banking violation | 2017 | FED | $175,000,000 |
Lloyds TSB Bank plc | Lloyds Banking Group | financial services | economic sanction violation | 2009 | NY-MANDA | $175,000,000 |
GlaxoSmithKline | GSK plc | pharmaceuticals | price-fixing or anti-competitive practices | 2004 | private lawsuit-federal | $175,000,000 |
Rolls-Royce plc | Rolls-Royce | aerospace and military contracting | Foreign Corrupt Practices Act | 2017 | DOJ_CRIMINAL | $169,917,710 |
HSBC HOLDINGS PLC | HSBC | financial services | banking violation | 2012 | FED | $165,000,000 |
Standard Chartered plc | Standard Chartered | financial services | banking violation | 2019 | FED | $164,000,000 |
SB Pharmco Puerto Rico Inc. | GSK plc | pharmaceuticals | drug or medical equipment safety violation | 2010 | MULTI-AG | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $163,560,000 |
Barclays Bank PLC | Barclays | financial services | price-fixing or anti-competitive practices | 2012 | DOJ_CRIMINAL | $160,000,000 |
BarclaysPLC | Barclays | financial services | price-fixing or anti-competitive practices | 2016 | private lawsuit-federal | $155,333,333 |
HSBC HoldingsPLC | HSBC | financial services | price-fixing or anti-competitive practices | 2016 | private lawsuit-federal | $155,333,333 |
Royal Bank of Scotland GroupPLC | NatWest Group PLC | financial services | price-fixing or anti-competitive practices | 2016 | private lawsuit-federal | $155,333,333 |
RBS Securities Inc. | NatWest Group PLC | financial services | toxic securities abuses | 2013 | SEC | $153,700,000 |
RBS PLC and RBS Securities Japan | NatWest Group PLC | financial services | price-fixing or anti-competitive practices | 2014 | DOJ_ANTITRUST | $150,000,000 |
GlaxoSmithKline | GSK plc | pharmaceuticals | False Claims Act and related | 2005 | DOJ_CIVIL | $150,000,000 |
Brown & Williamson Tobacco | British American Tobacco | tobacco | tobacco litigation | 2003 | MULTI-AG | $150,000,000 |
Atlantic Richfield | BP | oil and gas | environmental violation | 2020 | USAO | $150,000,000 |
Barclays Bank PLC | Barclays | financial services | price-fixing or anti-competitive practices | 2015 | NY-DFS | $150,000,000 |
GlaxoSmithKline PLC | GSK plc | pharmaceuticals | price-fixing or anti-competitive practices | 2013 | private lawsuit-federal | $150,000,000 |
Hikma Pharmaceuticals | Hikma Pharmaceuticals | pharmaceuticals | off-label or unapproved promotion of medical products | 2024 | MULTI-AG | $150,000,000 |
Deloitte & Touche LLP | Deloitte | business services | False Claims Act and related | 2018 | DOJ_CIVIL | $149,500,000 |
Barclays plc | Barclays | financial services | economic sanction violation | 2010 | NY-MANDA | (*)Penalty amounts marked by an asterisk are ones announced by more than one agency. Parent penalty totals are adjusted to avoid double-counting. $149,000,000 |
British Airways PLC | International Airlines Group | airlines | price-fixing or anti-competitive practices | 2008 | private lawsuit-federal | $139,000,000 |
Equilon Enterprises LLC | Shell PLC | oil and gas | air pollution violation | 2001 | EPA | $138,333,333 |